Drug Trial Radar · NCT07926997
Pharmacokinetics of Oral Zoliflodacin 3 g in Healthy Lactating Women
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Global Antibiotics Research and Development PartnershipAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-arm clinical trial to evaluate the PK profile in breast milk and plasma after a single oral dose of zoliflodacin in healthy lactating women. Eligible participants who have been actively breastfeeding or expressing milk for at least 4 weeks postpartum will receive a single dose of zoliflodacin administered as an oral suspension with food. Breast milk and plasma samples will be collected at predefined time points for up to 48 hours after dosing to characterize zoliflodacin concentrations and estimate drug exposure in breast milk and maternal plasma. Participants will temporarily discontinue breastfeeding from study check-in until 72 hours after dosing to avoid infant exposure to zoliflodacin. Breast milk will be expressed using an electronic breast pump and collected according to the study schedule. Participants will be admitted to the clinical research unit the day before dosing and discharged after completion of the 48-hour PK sampling period. A follow-up visit will be conducted approximately 7 days after dosing to assess safety and tolerability. A lactation consultant will be available throughout the study period and for up to 30 days after dosing, as needed.
Conditions
- Lactation
Interventions
ZoliflodacinDrug
Oral suspension of Zoliflodacin 3g
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Milk Concentration (Cmax) of Zoliflodacin in human milkTime frame: Through 48 hours post dose
- Time to Maximum Observed Concentration (Tmax) of Zoliflodacin in human milkTime frame: Through 48 hours post-dose.
- Terminal Elimination Half-Life (t½) of Zoliflodacin in human MilkTime frame: Through 48 hours post-dose.
- Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC₀-∞) of Zoliflodacin in Human MilkTime frame: Through 48 hours post-dose
- Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC₀-last) of Zoliflodacin in Human MilkTime frame: Through 48 hours post-dose
- Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC₀-24) of Zoliflodacin in Human MilkTime frame: 24 hours post-dose.
- Milk-to-Plasma Ratio for AUC₀-∞ of ZoliflodacinTime frame: Through 48 hours post-dose.
- Milk-to-Plasma Ratio for AUC₀-last of ZoliflodacinTime frame: Through 48 hours post-dose.
- Milk-to-Plasma Ratio for AUC₀-24 of ZoliflodacinTime frame: 24 hours post-dose
- Milk-to-Plasma Ratio for Cmax of ZoliflodacinTime frame: Through 48 hours post-dose.
- Relative Infant Dose (RID) of ZoliflodacinTime frame: Through 48 hours post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TrialMed
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.